Project Grant W81XWH1510005

This $2.9 million Defense Health Agency project grant funds research on suicide prevention among military personnel and veterans. The grant supports a multi-site randomized clinical trial through September 2026 to evaluate the efficacy of Written Exposure Therapy for Suicide Prevention compared to treatment as usual. Researchers at Boston University and partner institutions University of Colorado Denver and University of Texas Health Science Center San Antonio aim to reduce suicidal thoughts and...

This $2,763,615 federal Project Grant award from the Department of Defense's Military Medical Research and Development program (CFDA 12.420) supports a randomized controlled trial of brief prolonged exposure therapy for injured individuals admitted to a Level I trauma center. The goal is to evaluate the effectiveness of this approach in preventing post-traumatic stress disorder (PTSD) in this patient population. The 4-year study is being conducted by the Baylor Research Institute, a non-profit...

This Project Grant award of $2,384,097, provided by the Defense Health Agency through the Military Medical Research and Development (CFDA 12.420) federal grant program, is funding a hybrid experimental clinical trial to determine the optimal sequencing of interventions to maximize the effectiveness of PTSD treatment. The primary awardee, The University of Texas Health Science Center at San Antonio, will conduct this research with a planned completion date of August 2028. The project involves two...

The University of Texas Health Science Center of San Antonio will receive $3 million in cooperative agreement funding from the Department of the Army Medical Command to conduct a randomized clinical trial combining stellate ganglion block with prolonged exposure therapy for post-traumatic stress disorder (PTSD). The four-year award under the Military Medical Research and Development program (CFDA 12.420) aims to investigate medical solutions for traumatic battlefield injuries and transform...

This Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) provides $6,964,861.00 to The University of Texas Health Science Center at San Antonio to conduct a multi-year longitudinal study focused on military psychological health. The study has five specific aims: Conduct a prospective, longitudinal follow-up of 3,360 previous clinical trial participants treated for PTSD, sleep disorders, or chronic pain. Conduct a...

This federal Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), aims to develop and evaluate an adapted version of Written Exposure Therapy (WET) for treating posttraumatic stress disorder (PTSD) among individuals with opioid use disorder (OUD) in residential substance use disorder (SUD) treatment settings. The $798,605 award will fund a multi-site study to create and test the adapted "Written Exposure in...

EQUINE ASSISTED THERAPY FOR VETERANS The PTSD Foundation of America received a $245,417 Project Grant award dated September 30, 2025, from the Department of Veterans Affairs (VA) Veterans Health Administration Under Secretary for Health to implement equine-assisted therapy services for disabled veterans and members of the Armed Forces. Under the VA Grants for Adaptive Sports Programs for Disabled Veterans and Disabled Members of the Armed Forces (CFDA 64.034), this one-year performance period...

Federal Grant Award Summary The Defense Health Agency awarded $2.48M through the Military Medical Research and Development program (CFDA 12.420) to the Veterans Medical Research Foundation of San Diego on September 30, 2025, for a Phase 2A clinical trial evaluating the efficacy and safety of PT150 in treating posttraumatic stress disorder (PTSD) in U.S. military veterans. The four-year project, extending through September 29, 2029, will deliver randomized controlled clinical trial services,...

This federal Project Grant award, valued at $3,141,404.00 and issued by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program, supports a randomized controlled trial to evaluate the efficacy of combined cognitive processing therapy and stellate ganglion blocks for the treatment of post-traumatic stress disorder (PTSD). The award was granted to Rush University Medical Center, a prominent academic medical center in Chicago, Illinois, to conduct this...

The Defense Health Agency awarded a four-year, $936,532 Cooperative Agreement to the University of Texas Health Science Center at San Antonio (UTHSCSA) to implement and evaluate a patient-centered PTSD treatment program for military personnel. This award is funded under the Military Medical Research and Development (CFDA 12.420) program, which supports biomedical research to transform healthcare for service members and the public. Through this Cooperative Agreement, UTHSCSA will conduct research...